These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

287 related items for PubMed ID: 16884361

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. LyGDI is a promising biomarker for ovarian cancer.
    Zhen H, Yang S, Wu H, Wang S, Lv J, Ma L, Zhang X.
    Int J Gynecol Cancer; 2010 Apr; 20(3):316-22. PubMed ID: 20375790
    [Abstract] [Full Text] [Related]

  • 4. Elevated serum insulin-like growth factor-binding protein 2 (IGFBP-2) and decreased IGFBP-3 in epithelial ovarian cancer: correlation with cancer antigen 125 and tumor-associated trypsin inhibitor.
    Flyvbjerg A, Mogensen O, Mogensen B, Nielsen OS.
    J Clin Endocrinol Metab; 1997 Jul; 82(7):2308-13. PubMed ID: 9215312
    [Abstract] [Full Text] [Related]

  • 5. Expression of serum miR-200a, miR-200b, and miR-200c as candidate biomarkers in epithelial ovarian cancer and their association with clinicopathological features.
    Zuberi M, Mir R, Das J, Ahmad I, Javid J, Yadav P, Masroor M, Ahmad S, Ray PC, Saxena A.
    Clin Transl Oncol; 2015 Oct; 17(10):779-87. PubMed ID: 26063644
    [Abstract] [Full Text] [Related]

  • 6. Serum HE4 superior to CA125 in predicting poorer surgical outcome of epithelial ovarian cancer.
    Shen Y, Li L.
    Tumour Biol; 2016 Nov; 37(11):14765-14772. PubMed ID: 27629144
    [Abstract] [Full Text] [Related]

  • 7. Elevated serum 8-OHdG is associated with poor prognosis in epithelial ovarian cancer.
    Pylväs M, Puistola U, Laatio L, Kauppila S, Karihtala P.
    Anticancer Res; 2011 Apr; 31(4):1411-5. PubMed ID: 21508394
    [Abstract] [Full Text] [Related]

  • 8. Detection of epithelial ovarian cancer using 1H-NMR-based metabonomics.
    Odunsi K, Wollman RM, Ambrosone CB, Hutson A, McCann SE, Tammela J, Geisler JP, Miller G, Sellers T, Cliby W, Qian F, Keitz B, Intengan M, Lele S, Alderfer JL.
    Int J Cancer; 2005 Feb 20; 113(5):782-8. PubMed ID: 15499633
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Overexpression of salusin-β is associated with poor prognosis in ovarian cancer.
    Zhang Q, Chen WM, Zhang XX, Zhang HX, Wang HC, Zheng FY, Zhu FF.
    Oncol Rep; 2017 Mar 20; 37(3):1826-1832. PubMed ID: 28184918
    [Abstract] [Full Text] [Related]

  • 12. Prognostic and predictive relevance of CA-125 at primary surgery of ovarian cancer.
    Mury D, Woelber L, Jung S, Eulenburg C, Choschzick M, Witzel I, Schwarz J, Jaenicke F, Mahner S.
    J Cancer Res Clin Oncol; 2011 Jul 20; 137(7):1131-7. PubMed ID: 21344262
    [Abstract] [Full Text] [Related]

  • 13. Elevated serum insulin-like growth factor binding protein-2 as a prognostic marker in patients with ovarian cancer.
    Baron-Hay S, Boyle F, Ferrier A, Scott C.
    Clin Cancer Res; 2004 Mar 01; 10(5):1796-806. PubMed ID: 15014034
    [Abstract] [Full Text] [Related]

  • 14. Alterations in expression pattern of splicing factors in epithelial ovarian cancer and its clinical impact.
    Iborra S, Hirschfeld M, Jaeger M, Zur Hausen A, Braicu I, Sehouli J, Gitsch G, Stickeler E.
    Int J Gynecol Cancer; 2013 Jul 01; 23(6):990-6. PubMed ID: 23748175
    [Abstract] [Full Text] [Related]

  • 15. The utility of presurgical CA125 to predict optimal tumor cytoreduction of epithelial ovarian cancer.
    Barlow TS, Przybylski M, Schilder JM, Moore DH, Look KY.
    Int J Gynecol Cancer; 2006 Jul 01; 16(2):496-500. PubMed ID: 16681717
    [Abstract] [Full Text] [Related]

  • 16. Impact of Preoperative Serum Levels of CA 125 on Epithelial Ovarian Cancer Survival.
    Pradjatmo H, Pradjatmo H.
    Asian Pac J Cancer Prev; 2016 Jul 01; 17(4):1881-6. PubMed ID: 27221870
    [Abstract] [Full Text] [Related]

  • 17. Differential transcriptional and protein expression of thyroid-stimulating hormone receptor in ovarian carcinomas.
    Gyftaki R, Liacos C, Politi E, Liontos M, Saltiki K, Papageorgiou T, Thomakos N, Haidopoulos D, Rodolakis A, Alevizaki M, Bamias A, Dimopoulos A.
    Int J Gynecol Cancer; 2014 Jun 01; 24(5):851-6. PubMed ID: 24844218
    [Abstract] [Full Text] [Related]

  • 18. Characterization of miR-200 family members as blood biomarkers for human and laying hen ovarian cancer.
    Choi PW, Bahrampour A, Ng SK, Liu SK, Qiu W, Xie F, Kuo WP, Kwong J, Hales KH, Hales DB, Wong KK, Norwitz ER, Chow CK, Berkowitz RS, Ng SW.
    Sci Rep; 2020 Nov 18; 10(1):20071. PubMed ID: 33208870
    [Abstract] [Full Text] [Related]

  • 19. Intraoperative Diagnosis Support Tool for Serous Ovarian Tumors Based on Microarray Data Using Multicategory Machine Learning.
    Park JS, Choi SB, Kim HJ, Cho NH, Kim SW, Kim YT, Nam EJ, Chung JW, Kim DW.
    Int J Gynecol Cancer; 2016 Jan 18; 26(1):104-13. PubMed ID: 26512784
    [Abstract] [Full Text] [Related]

  • 20. Clinical Significance of Tissue Factor Pathway Inhibitor 2, a Serum Biomarker Candidate for Ovarian Clear Cell Carcinoma.
    Arakawa N, Kobayashi H, Yonemoto N, Masuishi Y, Ino Y, Shigetomi H, Furukawa N, Ohtake N, Miyagi Y, Hirahara F, Hirano H, Miyagi E.
    PLoS One; 2016 Jan 18; 11(10):e0165609. PubMed ID: 27798689
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.